Sermorelin: growth-hormone secretagogue research
Evaluating sermorelin claims without treating a GH-releasing peptide narrative as proof of benefit.
Educational information only — not medical advice. This page does not diagnose conditions, recommend treatment, or replace care from a qualified clinician. The Peptide Center uses an evidence-first editorial process: regulatory sources, trial registries, and peer-reviewed research take priority; uncertainty is stated rather than filled with promises.
Sermorelin is a growth-hormone-releasing hormone (GHRH) analogue studied in endocrine research. Historically, certain sermorelin products had FDA-approved diagnostic uses; many products discussed online today are not FDA-approved medicines and should not be described as such without verification.
References
- Therapeutic peptides: recent advances in discovery, synthesis, and clinical applications. Signal Transduction and Targeted Therapy, 2022
- ClinicalTrials.gov: Learn about studies
- FDA: The drug development process
Related resources
Continue with curated, same-topic resources from the published library. These links are educational references, not treatment recommendations.